Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland

Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland

Here, Simpson et al. analyze data from 3.6 million COVID-19 vaccine second doses (ChAdOx1 and BNT162b2) in Scotland for risk of thrombocytopenic, thromboembolic and hemorrhagic events. Borderline increased risks of immune thrombocytopenic purpura and cerebral venous sinus thrombosis were found for t...

Full description

Bibliographic Details
Main Authors: Colin R. Simpson, Steven Kerr, Srinivasa Vittal Katikireddi, Colin McCowan, Lewis D. Ritchie, Jiafeng Pan, Sarah J. Stock, Igor Rudan, Ruby S. M. Tsang, Simon de Lusignan, F. D. Richard Hobbs, Ashley Akbari, Ronan A. Lyons, Chris Robertson, Aziz Sheikh
Format: Article
Language:English
Published: Nature Portfolio 2022-08-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-022-32264-6

Internet

https://doi.org/10.1038/s41467-022-32264-6

Similar Items